Pregnant women who experienced severe symptoms of COVID-19 had a higher risk of complications during and after pregnancy, according to preliminary findings from a National Institutes of Health study. Compared to COVID-19 patients without symptoms, those with severe symptoms were at higher risk for cesarean delivery, postpartum hemorrhage, hypertensive disorders of pregnancy and preterm birth.
Milken Institute School of Public Health Launches New Study of Deaths in Puerto Rico Due to Hurricane Maria
The Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University (GW) today announced receiving nearly $1 million in a contract award from the National Institute of Standards and Technology (NIST) to identify deaths in Puerto Rico directly and indirectly tied to Hurricane Maria – especially those associated with building failures.
Professors John Lachin (Research Professor of Biostatistics and Sharon Edelstein (Lead Biostatistician Manager) of the Biostatistics Center, rank at the top for most cited research.
See full article here
These important projects will help us understand the distribution and effects of COVID-19, particularly on underserved populations, ultimately improving public health,” said Scott Evans, PhD, Director of the GW BSC and Founding Chair of the Department of Biostatistics and Bioinformatics at Milken Institute SPH.
See full article here
The Maternal Fetal Medicine Units Network (MFMU Network), which includes The Biostatistics Center based at the George Washington University Milken Institute School of Public Health, has received funding from the National Institutes of Health (NIH) to study opioid prescription patterns and pain management after a cesarean delivery.
Scott Evans, Director of the Biostatistics Center, Professor and founding Chair of the new Department of Biostatistics and Bioinformatics has received and $18.6 million award for leadership of the Statistical and Data Management Center for the Antibacterial Resistance Leadership Group (ARLG), a collaborative clinical research network that prioritizes, designs, and executes clinical research to reduce the public health threat of antibacterial resistance.